Autologous Hematopoietic Stem Cell Mobilization (Plerixafor) and Immunologic Reset in New Onset Type 1 Diabetes Mellitus
Latest Information Update: 23 Jul 2024
At a glance
- Drugs Alemtuzumab (Primary) ; Anakinra (Primary) ; Etanercept (Primary) ; Liraglutide (Primary) ; Plerixafor (Primary)
- Indications Type 1 diabetes mellitus
- Focus Adverse reactions; Pharmacokinetics
- 19 Jul 2024 Status changed from active, no longer recruiting to completed.
- 24 Jul 2023 Planned primary completion date changed from 10 Jul 2023 to 10 Jul 2024.
- 18 Jul 2023 Planned primary completion date changed from 30 Dec 2025 to 10 Jul 2023.